CrossrefInfokarte
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
Clinical Drug Investigation · 2024-08 · 44 (8) · 553-576
DOI: 10.1007/s40261-024-01379-7 ↗Abstract
Kein Abstract verfügbar.
EUVIMED